Nearly 3 million people in the United States and 65 million people worldwide have epilepsy, a neurological condition which affects the nervous system and causes seizures. One in 26 people will develop epilepsy at some point in their lifetime, with 150,000 new cases annually in the United States. Nearly 80% of the people with epilepsy live in low- and middle-income countries and three-quarters of these individuals do not get the treatment they need.
Among those living with epilepsy, nearly one-third have ongoing seizures despite existing therapies. Each year, more than 1 out of 1,000 people with epilepsy die from sudden unexpected death in epilepsy (SUDEP). If seizures are uncontrolled, the risk of SUDEP increases to more than 1 out of 150. SUDEP is the leading cause of death in young adults with uncontrolled seizures.
In order to accelerate the identification of effective treatments for SUDEP, the Epilepsy Foundation SUDEP Institute is sponsoring a Reduction to Practice Challenge to develop a predictive biomarker or panel of biomarkers to identify people at risk for SUDEP or seizures that compromise cardiac or respiratory function. The biomarker(s) must serve as an endpoint or surrogate endpoint that will drive human SUDEP interventions. For example, the biomarker(s) may identify a high risk patient group that could be used to test existing candidate interventions such as seizure detection devices.
Milestone 1 requires a detailed Project Plan of the proposed solution. Milestone 2 involves the production of proof-of-concept data. Milestone 3 requires results that demonstrate the predictive efficacy of the biomarker(s). The SUDEP Institute intends to make up to 10 awards from a total award pool of $100,000 for Milestone 1, up to 4 awards of $25,000 each for Milestone 2, and a final award at least $800,000 for successful completion of Milestone 3.
The challenge is looking for novel ideas and technologies that can be applied to achieve fast detection and identification of viable microorganisms and determination of antibiotic susceptibility which will enable faster diagnosis of infections caused by bacteria, for example sepsis and tuberculosis, and lead to more effective therapy and better patient outcomes.
Our Seeker Client, FasterCures, a nonprofit organization, is looking for novel approaches/incentives that can reduce the first-mover disadvantage and induce companies to invest more in biomarkers research and qualification, while not limiting their availability to others.
Read Challenge Details for Challenge 7273006
The Seeker is looking for a comprehensive approach - perhaps using some data mining tools involving classification and regression trees, cluster analysis, etc. – for each of two related problems. Both problems involve analyzing a wide range of covariates that may help (a) identify sub-groups of patients who have a differential response to treatment, and (b) predict responders and non-responders in clinical trials.
The Seeker is soliciting ideas for improvements to the United States Health care system. The key requirement is that the idea must be able to be implemented quickly and effectively. This is an Ideation challenge so your creativity and common sense qualify you to participate in this challenge. Please limit your responses to about 2 written pages.
Read Challenge Details for Challenge 6211731
The Seeker is looking for a comprehensive analysis of available data on the prevalence of seizures in patients with schizophrenia as well as the incidence of new seizures in patients taking anti-psychotic medication. This is a theoretical challenge that requires a detailed, written research report.
A design for dry-based biolatrines for rural schools in Africa is needed. The biolatrines will contribute to efforts to improve sanitation and water preservation in parts of Africa struggling with increased demand for safe water. This challenge is sponsored by the Rockefeller Foundation and requires only a written proposal.
Read Challenge Details for Challenge 5676808
Theoretical proposals for a safe and economical synthetic route to the shown nitroimidazole are desired. The route you propose should be more economical than the publicly disclosed routes.
The development of PA-824 is being directed by the Global Alliance for TB Drug Development, a not-for-profit, product development partnership accelerating the discovery and development of new TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies used for HIV/AIDS, and improve treatment of latent infection. The Rockefeller Foundation is sponsoring the current InnoCentive Challenge.
More details are available after you have registered as an InnoCentive Solver.